SCYNEXIS (STU:135) E10: €-37.22 (As of Mar. 2026)


STU:135 SCYNEXIS Inc STU:135
40 GF Score
Price €4.84
GF Value €29.55
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is SCYNEXIS E10?

SCYNEXIS STU:135 40 E10 is €-37.22 as of Mar. 2026. GuruFocus rates STU:135 with a GF Score™ of 40/100 and a GF Value™ of €29.55 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

SCYNEXIS's adjusted earnings per share data for the three months ended in Mar. 2026 was €-2.906. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-37.22 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 50.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of SCYNEXIS was 50.40% per year. The lowest was 50.40% per year. And the median was 50.40% per year.

As of today (2026-06-26), SCYNEXIS's current stock price is €4.84. SCYNEXIS's E10 for the quarter that ended in Mar. 2026 was €-37.22. SCYNEXIS's Shiller PE Ratio of today is .


SCYNEXIS  (STU:135) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


SCYNEXIS E10 Related Terms


SCYNEXIS E10 Historical Data

* Premium members only.

The historical data trend for SCYNEXIS's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SCYNEXIS E10 Chart

SCYNEXIS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -339.92 -83.54 -58.95 -39.59

SCYNEXIS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -65.52 -50.81 -62.85 -39.59 -37.22

STU:135 vs ETST, BGM, INCR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Shiller PE Ratio falls into.


STU:135
40GF Score
SCYNEXIS Inc STU:135
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SCYNEXIS E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SCYNEXIS's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-2.906/330.2130*330.2130
=-2.906

Current CPI (Mar. 2026) = 330.2130.

SCYNEXIS Quarterly Data

per share eps CPI Adj_EPS
201606 -39.872 241.018 -54.628
201609 -34.214 241.428 -46.796
201612 -3.792 241.432 -5.186
201703 -18.700 243.801 -25.328
201706 -11.392 244.955 -15.357
201709 -20.807 246.819 -27.837
201712 -18.252 246.524 -24.448
201803 -7.786 249.554 -10.303
201806 -15.750 251.989 -20.639
201809 0.686 252.439 0.897
201812 4.219 251.233 5.545
201903 -32.568 254.202 -42.306
201906 -11.186 256.143 -14.421
201909 -10.533 256.759 -13.546
201912 -15.408 256.974 -19.799
202003 -5.213 258.115 -6.669
202006 -4.547 257.797 -5.824
202009 -1.902 260.280 -2.413
202012 -25.778 260.474 -32.680
202103 -1.546 264.877 -1.927
202106 -1.461 271.696 -1.776
202109 -0.408 274.310 -0.491
202112 -7.859 278.802 -9.308
202203 -1.308 287.504 -1.502
202206 -2.346 296.311 -2.614
202209 -5.010 296.808 -5.574
202212 -2.190 296.797 -2.437
202303 -5.305 301.836 -5.804
202306 18.165 305.109 19.660
202309 -0.300 307.789 -0.322
202312 -3.008 306.746 -3.238
202403 0.074 312.332 0.078
202406 -2.230 314.175 -2.344
202409 -0.432 315.301 -0.452
202412 -0.688 315.605 -0.720
202503 -0.814 319.799 -0.841
202506 -0.971 322.561 -0.994
202509 -1.159 324.800 -1.178
202512 1.708 324.054 1.740
202603 -2.906 330.213 -2.906

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-37.22 mean?
SCYNEXIS (STU:135) has a E10 of €-37.22 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on SCYNEXIS and its competitors.
Is SCYNEXIS's E10 too high?
SCYNEXIS's current E10 is €-37.22. Overall, SCYNEXIS has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's E10 compare to ETST and BGM?
SCYNEXIS's E10 of €-37.22 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on SCYNEXIS and its competitors. SCYNEXIS's current E10 is €-37.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
Based on GuruFocus' analysis, SCYNEXIS (STU:135) is currently considered Possible Value Trap. The stock's GF Value™ is €29.55, compared to a current price of €4.84 — trading 83.6% below its estimated fair value. The current E10 is €-37.22. SCYNEXIS's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For SCYNEXIS (STU:135), the current E10 is €-37.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SCYNEXIS (STU:135) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of €4.84 is trading 83.6% below its estimated GF Value™ of €29.55. GuruFocus considers SCYNEXIS to be Possible Value Trap.

Key valuation signals for STU:135:

  • E10: €-37.22
  • GF Value™: €29.55 vs. price of €4.84 (83.6% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the STU:135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SCYNEXIS Business Description

Other Exchanges SCYX:USA0L49:UK
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
40GF Score

Get the complete analysis for STU:135

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.84
Price
€29.55
GF Value